Skip to main content
Alzheimer Disease
Resource Center
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
COVID-19
Depression Care 360
HIV Management
HIV Prevention
Pediatric Influenza
Psoriatic Arthritis
Resources
Commentary
Disease State Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&As
Quizzes
Research Summaries
Slideshows
Videos
Events & Education
Consultant360's Practical Updates in Primary Care
CME
Publication
About Consultant
Consultant Current Issue
Consultant Early View
Consultant Archive
Author Guidelines
Case Report Templates
FAQ
Advertising With Consultant360
Search
Login
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
COVID-19
Depression Care 360
HIV Management
HIV Prevention
Pediatric Influenza
Psoriatic Arthritis
Resources
Commentary
Disease State Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&As
Quizzes
Research Summaries
Slideshows
Videos
Events & Education
Consultant360's Practical Updates in Primary Care
CME
Publication
About Consultant
Consultant Current Issue
Consultant Early View
Consultant Archive
Author Guidelines
Case Report Templates
FAQ
Advertising With Consultant360
treatment outcomes
Poll: Impact of Impact of Lecanemab on Treating Alzheimer Disease
01/13/2023
Copied to clipboard
<section><h2><h2>In your opinion, do you believe the recent FDA approval of lecanemab is a serious breakthrough in the treatment of Alzheimer disease?</h2></h2></section><section><h2>Yes, the recent FDA approval gives me confidence that this is a major breakthrough in how we treat Alzheimer disease.</h2></section><section><h3>No, there are still too many uncertainties regarding this treatment.</h3></section><section><h3>I am cautiously optimistic about the impact of the new treatment.</h3></section><section><h3>Even with the FDA’s approval, it’s too early to tell whether lecanemab is a major breakthrough.</h3></section>
